Browsing by Author "Moon Nyeo Park"

Now showing 1 - 5 of 5

Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review
(Frontiers Media S.A., 2022) Anandakrishnan Karthic; Arpita Roy; Jaya Lakkakula; Saad Alghamdi; Afnan Shakoori; Ahmad O. Babalghith; Talha Bin Emran; Rohit Sharma; Clara Mariana Gonçalves Lima; Bonglee Kim; Moon Nyeo Park; Sher Zaman Safi; Ray Silva de Almeida; Henrique Douglas Melo Coutinho
Cancer is still one of the world’s deadliest health concerns. As per latest statistics, lung, breast, liver, prostate, and cervical cancers are reported topmost worldwide. Although chemotherapy is most widely used methodology to treat cancer, poor pharmacokinetic parameters of anticancer drugs render them less effective. Novel nano-drug delivery systems have the caliber to improve the solubility and biocompatibility of various such chemical compounds. In this regard, cyclodextrins (CD), a group of natural nano-oligosaccharide possessing unique physicochemical characteristics has been highly exploited for drug delivery and other pharmaceutical purposes. Their cup-like structure and amphiphilic nature allows better accumulation of drugs, improved solubility, and stability, whereas CDs supramolecular chemical compatibility renders it to be highly receptive to various kinds of functionalization. Therefore combining physical, chemical, and bio-engineering approaches at nanoscale to specifically target the tumor cells can help in maximizing the tumor damage without harming non-malignant cells. Numerous combinations of CD nanocomposites were developed over the years, which employed photodynamic, photothermal therapy, chemotherapy, and hyperthermia methods, particularly targeting cancer cells. In this review, we discuss the vivid roles of cyclodextrin nanocomposites developed for the treatment and theranostics of most important cancers to highlight its clinical significance and potential as a medical tool. Copyright © 2022 Karthic, Roy, Lakkakula, Alghamdi, Shakoori, Babalghith, Emran, Sharma, Lima, Kim, Park, Safi, de Almeida and Coutinho.
Development of new bioactive molecules to treat breast and lung cancer with natural myricetin and its derivatives: A computational and SAR approach
(Frontiers Media S.A., 2022) Shopnil Akash; Ajoy Kumer; Md. Mominur Rahman; Talha Bin Emran; Rohit Sharma; Rajeev K. Singla; Fahad A. Alhumaydhi; Mayeen Uddin Khandaker; Moon Nyeo Park; Abubakr M. Idris; Polrat Wilairatana; Bonglee Kim
Each biopharmaceutical research and new drug development investigation is targeted at discovering novel and potent medications for managing specific ailments. Thus, to discover and develop new potent medications, it should be performed sequentially or step by step. This is because drug development is a lengthy and risky work that requires significant money, resources, and labor. Breast and lung cancer contributes to the death of millions of people throughout the world each year, according to the report of the World Health Organization, and has been a public threat worldwide, although the global medical sector is developed and updated day by day. However, no proper treatment has been found until now. Therefore, this research has been conducted to find a new bioactive molecule to treat breast and lung cancer—such as natural myricetin and its derivatives—by using the latest and most authentic computer-aided drug-design approaches. At the beginning of this study, the biological pass prediction spectrum was calculated to select the target protein. It is noted that the probability of active (Pa) score is better in the antineoplastic (Pa: 0.788–0.938) in comparison with antiviral (Pa: 0.236–0.343), antibacterial (Pa: 0.274–0.421), and antifungal (Pa: 0.226–0.508). Thus, cancerous proteins, such as in breast and lung cancer, were picked up, and the computational investigation was continued. Furthermore, the docking score was found to be -7.3 to -10.4 kcal/mol for breast cancer (standard epirubicin hydrochloride, -8.3 kcal/mol), whereas for lung cancer, the score was -8.2 to -9.6 kcal/mol (standard carboplatin, -5.5 kcal/mol). The docking score is the primary concern, revealing that myricetin derivatives have better docking scores than standard chemotherapeutic agents epirubicin hydrochloride and carboplatin. Finally, drug-likeness, ADME, and toxicity prediction were fulfilled in this investigation, and it is noted that all the derivatives were highly soluble in a water medium, whereas they were totally free from AMES toxicity, hepatotoxicity, and skin sensitization, excluding only ligands 1 and 7. Thus, we proposed that the natural myricetin derivatives could be a better inhibitor for treating breast and lung cancer. Copyright © 2022 Akash, Kumer, Rahman, Emran, Sharma, Singla, Alhumaydhi, Khandaker, Park, Idris, Wilairatana and Kim.
Exploring the recent trends in perturbing the cellular signaling pathways in cancer by natural products
(Frontiers Media S.A., 2022) Md. Mominur Rahman; Md. Taslim Sarker; Mst. Afroza Alam Tumpa; Md. Yamin; Tamanna Islam; Moon Nyeo Park; Md. Rezaul Islam; Abdur Rauf; Rohit Sharma; Simona Cavalu; Bonglee Kim
Cancer is commonly thought to be the product of irregular cell division. According to the World Health Organization (WHO), cancer is the major cause of death globally. Nature offers an abundant supply of bioactive compounds with high therapeutic efficacy. Anticancer effects have been studied in a variety of phytochemicals found in nature. When Food and Drug Administration (FDA)-approved anticancer drugs are combined with natural compounds, the effectiveness improves. Several agents have already progressed to clinical trials based on these promising results of natural compounds against various cancer forms. Natural compounds prevent cancer cell proliferation, development, and metastasis by inducing cell cycle arrest, activating intrinsic and extrinsic apoptosis pathways, generating reactive oxygen species (ROS), and down-regulating activated signaling pathways. These natural chemicals are known to affect numerous important cellular signaling pathways, such as NF-B, MAPK, Wnt, Notch, Akt, p53, AR, ER, and many others, to cause cell death signals and induce apoptosis in pre-cancerous or cancer cells without harming normal cells. As a result, non-toxic “natural drugs” taken from nature’s bounty could be effective for the prevention of tumor progression and/or therapy of human malignancies, either alone or in combination with conventional treatments. Natural compounds have also been shown in preclinical studies to improve the sensitivity of resistant cancers to currently available chemotherapy agents. To summarize, preclinical and clinical findings against cancer indicate that natural-sourced compounds have promising anticancer efficacy. The vital purpose of these studies is to target cellular signaling pathways in cancer by natural compounds. Copyright © 2022 Rahman, Sarker, Alam Tumpa, Yamin, Islam, Park, Islam, Rauf, Sharma, Cavalu and Kim.
Fucoxanthin: A Promising Phytochemical on Diverse Pharmacological Targets
(Frontiers Media S.A., 2022) Mumtaza Mumu; Ayan Das; Talha Bin Emran; Saikat Mitra; Fahadul Islam; Arpita Roy; Md. Mobarak Karim; Rajib Das; Moon Nyeo Park; Deepak Chandran; Rohit Sharma; Mayeen Uddin Khandaker; Abubakr M. Idris; Bonglee Kim
Fucoxanthin (FX) is a special carotenoid having an allenic bond in its structure. FX is extracted from a variety of algae and edible seaweeds. It has been proved to contain numerous health benefits and preventive effects against diseases like diabetes, obesity, liver cirrhosis, malignant cancer, etc. Thus, FX can be used as a potent source of both pharmacological and nutritional ingredient to prevent infectious diseases. In this review, we gathered the information regarding the current findings on antimicrobial, antioxidant, anti-inflammatory, skin protective, anti-obesity, antidiabetic, hepatoprotective, and other properties of FX including its bioavailability and stability characteristics. This review aims to assist further biochemical studies in order to develop further pharmaceutical assets and nutritional products in combination with FX and its various metabolites. Copyright © 2022 Mumu, Das, Emran, Mitra, Islam, Roy, Karim, Das, Park, Chandran, Sharma, Khandaker, Idris and Kim.
Natural Small Molecules in Gastrointestinal Tract and Associated Cancers: Molecular Insights and Targeted Therapies
(MDPI, 2022) Fahadul Islam; Saikat Mitra; Talha Bin Emran; Zidan Khan; Nikhil Nath; Rajib Das; Rohit Sharma; Ahmed Abdullah Al Awadh; Moon Nyeo Park; Bonglee Kim
Gastric cancer is one of the most common cancers of the gastrointestinal tract. Although surgery is the primary treatment, serious maladies that dissipate to other parts of the body may require chemotherapy. As there is no effective procedure to treat stomach cancer, natural small molecules are a current focus of research interest for the development of better therapeutics. Chemotherapy is usually used as a last resort for people with advanced stomach cancer. Anti-colon cancer chemotherapy has become increasingly effective due to drug resistance and sensitivity across a wide spectrum of drugs. Naturally-occurring substances have been widely acknowledged as an important project for discovering innovative medications, and many therapeutic pharmaceuticals are made from natural small molecules. Although the beneficial effects of natural products are as yet unknown, emerging data suggest that several natural small molecules could suppress the progression of stomach cancer. Therefore, the underlying mechanism of natural small molecules for pathways that are directly involved in the pathogenesis of cancerous diseases is reviewed in this article. Chemotherapy and molecularly-targeted drugs can provide hope to colon cancer patients. New discoveries could help in the fight against cancer, and future stomach cancer therapies will probably include molecularly formulated drugs. © 2022 by the authors.